Top

Archives of Gynecology and Obstetrics

Published in:

01-08-2013 | Gynecologic Oncology

Olaparib: a promising PARP inhibitor in ovarian cancer therapy

Authors: Ying Chen, Lei Zhang, Quan Hao

Published in: Archives of Gynecology and Obstetrics | Issue 2/2013

Abstract

Background

Ovarian cancer (OC) is the leading cause of death in women with gynecological cancer. Most patients are diagnosed at advanced stage with poor prognosis. Currently, surgical tumor debulking followed by chemotherapy based on platinum and taxane is the standard treatment for advanced OC. However, these patients remain at great risk for recurrence and developing drug resistance. Therefore, new treatment strategies are needed to improve outcomes for patients with advanced and recurrent OC. Olaparib (AZD2281, KU-0059436), as one of the best understood Poly-(ADP-ribose) polymerase (PARP) inhibitor targeting DNA repair mechanisms, caused more and more attention. Clinical trial data of Olaparib had been cumulated, which applied as the single-agent in relapsed OC monotherapy, especially for BRCA mutation associated OC.

Methods

In this review, we demonstrated the mechanism of PARP inhibitors and summarized clinical trial data and clinical development of Olaparib targeted OC in order to address a new promising therapy strategy for advanced relapsed OC.

Conclusion

Given the unprecedented clinical potential of Olaparib, the further research on Olaparib will have great significance in selection of OC patient populations that will respond to treatment.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef

Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114(1):26–31PubMedCrossRef

Chambon P, Weill JD, Mandel P (1963) Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11:39–43PubMedCrossRef

Langelier MF, Servent KM, Rogers EE, Pascal JM (2008) A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation. J Biol Chem 283(7):4105–4114PubMedCrossRef

Tao Z, Gao P, Hoffman DW, Liu HW (2008) Domain C of human poly(ADP-ribose) polymerase-1 is important for enzyme activity and contains a novel zinc-ribbon motif. Biochemistry 47(21):5804–5813PubMedCrossRef

Hassa PO, Haenni SS, Elser M, Hottiger MO (2006) Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev 70(3):789–829PubMedCrossRef

de Murcia G, Schreiber V, Molinete M, Saulier B, Poch O, Masson M, Niedergang C (1994) Ménissier de Murcia J. Structure and function of poly(ADP-ribose) polymerase. Mol Cell Biochem 138(1–2):15–24PubMedCrossRef

Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10(4):293–301PubMedCrossRef

Clark JB, Ferris GM, Pinder S (1971) Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5′-methyl nicotinamide. Biochim Biophys Acta 238(1):82–85PubMedCrossRef

10.

Durkacz BW, Omidiji O, Gray DA, Shall S (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283(5747):593–596PubMedCrossRef

11.

Weil MK, Chen AP (2011) PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer 35(1):7–50PubMedCrossRef

12.

Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A et al (2008) 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51(20):6581–6591PubMedCrossRef

13.

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134PubMedCrossRef

14.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366(15):1382–1392PubMedCrossRef

15.

Kaye SB, Lubinski J, Matulonis U et al (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30(4):372–379PubMedCrossRef

16.

Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12(9):852–861PubMedCrossRef

17.

Yamamoto N, Nokihara H, Yamada Y et al (2012) A phase I, dose-finding and pharmacokinetic study of Olaparib (AZD2281) in Japanese patients with advanced solid tumours. Cancer Sci 103(3):504–509PubMedCrossRef

18.

Audeh MW, Carmichael J, Penson RT et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737):245–251PubMedCrossRef

19.

Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26(22):3785–3790PubMedCrossRef

20.

Underhill C, Toulmonde M, Bonnefoi H (2011) A review of PARP inhibitors: from bench to bedside. Ann Oncol 22(2):268–279PubMedCrossRef

21.

Fong PC, Yap TA, Boss DS et al (2010) Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512–2519PubMedCrossRef

22.

Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312–3322PubMed

23.

Adams SF, Marsh EB, Elmasri W et al (2011) A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol 123(3):486–491PubMedCrossRef

24.

Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T, Bellati F (2012) Benedetti Panici P. Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin Investig Drugs 21(10):1575–1584PubMedCrossRef

25.

Palma JP, Rodriguez LE, Bontcheva-Diaz VD et al (2008) The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 28(5A):2625–2635PubMed

26.

Donawho CK, Luo Y, Luo Y et al (2007) ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumour models. Clin Cancer Res 13(9):2728–2737PubMedCrossRef

27.

Carden CP, Yap TA, Kaye SB (2010) PARP inhibition: targeting the Achilles’ heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 22(5):473–480PubMedCrossRef

28.

Samol J, Ranson M, Scott E et al (2011) Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, Olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumours: a phase I study. Invest New Drugs 30(4):1493–1500PubMedCrossRef

29.

Khan OA, Gore M, Lorigan P et al (2011) A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 104:750–755PubMedCrossRef

30.

Dent RA, Lindeman GJ, Clemons M et al (2011) Safety and efficacy of the oral PARP inhibitor Olaparib (AZD2281) in combination with paclitaxel for the first or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 28(15S):1018 (abstract)

31.

Rajan A, Carter CA, Kelly RJ et al (2012) A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumours. Clin Cancer Res 18(8):2344–2351PubMedCrossRef

32.

Dean E, Middleton MR, Pwint T et al (2012) Phase I study to assess the safety and tolerability of Olaparib in combination with Bevacizumab in patients with advanced solid tumours. Br J Cancer 106(3):468–474PubMedCrossRef

33.

Chan N, Bristow RG (2010) Contextual synthetic lethality and/or loss of heterozygosity: tumour hypoxia and modification of DNA repair. Clin Cancer Res 16:4553–4560PubMedCrossRef

Title: Olaparib: a promising PARP inhibitor in ovarian cancer therapy
Authors: Ying Chen
Lei Zhang
Quan Hao
Publication date: 01-08-2013
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 2/2013
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-013-2856-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Olaparib: a promising PARP inhibitor in ovarian cancer therapy

Abstract

Background

Methods

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2013

Diastasis of rectus abdominis in the immediate puerperium: correlation between imaging diagnosis and clinical examination

Fetal uvula: navigating and lightening the soft palate using HDlive

Polymorphisms in genes RFC-1/CBS as maternal risk factors for Down syndrome in China

The sequence of intrapartum interventions: a descriptive approach to the cascade of interventions

Transvaginal sono-guided aspiration of gestational sac concurrent with a local methotrexate injection for the treatment of unruptured cesarean scar pregnancy

Endometrial stromal sarcoma: clinicopathological and immunophenotypic study of 16 cases